Profil

ABANKWA Daniel

University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM)

ORCID
0000-0003-2769-0745
Main Referenced Co-authors
MANOHARAN, Ganesh Babu  (10)
CHIPPALKATTI, Rohan  (8)
PAVIC, Karolina  (5)
LAURINI, Christina  (4)
PARISI, Bianca  (4)
Main Referenced Keywords
Ras (5); RAS (3); cancer (2); Humans (2); K-Ras (2);
Main Referenced Unit & Research Centers
Luxembourg Centre for Systems Biomedicine (LCSB): Biomedical Data Science (Glaab Group) (1)
Main Referenced Disciplines
Biochemistry, biophysics & molecular biology (34)
Human health sciences: Multidisciplinary, general & others (2)
Life sciences: Multidisciplinary, general & others (2)
Immunology & infectious disease (1)
Biotechnology (1)

Publications (total 37)

The most downloaded
777 downloads
Sahlgren, C., Meinander, A., Zhang, H., Cheng, F., Preis, M., Xu, C., Salminen, T., Toivola, D., Abankwa, D., Rosling, A., Karaman, D., Salo-Ahen, O., Österbacka, R., Eriksson, J., Willför, S., Petre, I., Peltonen, J., Leino, R., Johnson, M., ... Sandler, N. (2017). Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems. Advanced Healthcare Materials. doi:10.1002/adhm.201700258 https://hdl.handle.net/10993/34123

The most cited

37 citations (Scopus®)

Sahlgren, C., Meinander, A., Zhang, H., Cheng, F., Preis, M., Xu, C., Salminen, T., Toivola, D., Abankwa, D., Rosling, A., Karaman, D., Salo-Ahen, O., Österbacka, R., Eriksson, J., Willför, S., Petre, I., Peltonen, J., Leino, R., Johnson, M., ... Sandler, N. (2017). Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems. Advanced Healthcare Materials. doi:10.1002/adhm.201700258 https://hdl.handle.net/10993/34123

PARISI, B., Sünnen, M., CHIPPALKATTI, R., & ABANKWA, D. (10 October 2023). A flow-cytometry-based pipeline for the rapid quantification of C2C12 cell differentiation. STAR Protocols, 4 (4), 102637. doi:10.1016/j.xpro.2023.102637
Peer Reviewed verified by ORBi

CHIPPALKATTI, R., PARISI, B., Kouzi, F., LAURINI, C., Ben Fredj, N., & ABANKWA, D. (2023). RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation. Cold Spring Harbor Laboratory. doi:10.1101/2023.10.05.561021

MANOHARAN, G. B., STEFFEN, C., PAVIC, K., Yeste-Vázquez, A., Knuuttila, M., Arora, N., Zhou, Y., Härmä, H., GAIGNEAUX, A., Grossmann, T. N., & ABANKWA, D. (2023). Identification of an H-Ras nanocluster disrupting peptide. Cold Spring Harbor Laboratory. doi:10.1101/2023.09.07.556635

KAYA, P., SCHAFFNER-RECKINGER, E., MANOHARAN, G. B., Vukic, V., Kiriazis, A., LEDDA, M., Burgos, M., PAVIC, K., GAIGNEAUX, A., GLAAB, E., & ABANKWA, D. (2023). An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/58308. doi:10.1101/2023.08.23.554263

Steffen, C., Kaya, P., Schaffner-Reckinger, E., & Abankwa, D. (2023). Eliminating oncogenic RAS: back to the future at the drawing board. Biochemical Society Transactions. doi:10.1042/BST20221343
Peer Reviewed verified by ORBi

Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., Abankwa, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., ... Westermarck, J. (2023). Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications, 14 (1), 1143. doi:10.1038/s41467-023-36693-9
Peer Reviewed verified by ORBi

Manoharan, G. B., Guzmán, C., Najumudeen, A. K., & Abankwa, D. (2023). Detection of Ras nanoclustering-dependent homo-FRET using fluorescence anisotropy measurements. European Journal of Cell Biology. doi:10.1016/j.ejcb.2023.151314
Peer Reviewed verified by ORBi

Manoharan, G. B., Laurini, C., Bottone, S., Ben Fredj, N., & Abankwa, D. (2023). K-Ras Binds Calmodulin-Related Centrin1 with Potential Implications for K-Ras Driven Cancer Cell Stemness. Cancers. doi:10.3390/cancers15123087
Peer Reviewed verified by ORBi

CHIPPALKATTI, R.* , PARISI, B.* , YACOUB KOUZI, F., BEN FREDJ EP SOUA, N., LAURINI, C., & ABANKWA, D. (2023). A medium-throughput assay to profile the impact of Ras-disease mutants and -drugs on cellular differentiation [Paper presentation]. Tumor Heterogeneity, Plasticity and Therapy (2nd edition), Leuven, Belgium.
* These authors have contributed equally to this work.

Yashar Rouzbahani, CHIPPALKATTI, R., ABANKWA, D., Anindita Dasgupta, Pablo Carravilla, & Christian Eggeling. (2023). Adaptation of microscopy for studying cell polarization. In N.A. N.A. doi:10.1117/12.2666385

KAYA, P., SCHAFFNER-RECKINGER, E., MANOHARAN, G. B., Saley, B., & ABANKWA, D. (18 October 2022). Novel High Affinity Inhibitors Of The K-Ras Trafficking Chaperone PDE6D [Paper presentation]. The Fourth RAS Initiative Symposium, Frederick, United States.
Peer reviewed

MANOHARAN, G. B., PAVIC, K., Yeste Vazquez, A., Knuuttila, M., Grossmann, T. N., ABANKWA, D., & STEFFEN, C. (13 September 2022). Identification of a small peptide targeting the Raf/ Galectin interface to disrupt stabilised Ras signalling nanocluster [Paper presentation]. Small G proteins in cellular signalling and disease, Liverpool, United Kingdom.

Manoharan, G. B., Okutachi, S., & Abankwa, D. (2022). Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells. PLoS ONE. doi:10.1371/journal.pone.0268635
Peer Reviewed verified by ORBi

Pavic, K., Chippalkatti, R., & Abankwa, D. (2022). Drug targeting opportunities en route to Ras nanoclusters. Advances in Cancer Research, 153, 63-99. doi:10.1016/bs.acr.2021.07.005
Peer Reviewed verified by ORBi

Cipriani, C., Pires Pacheco, M. I., Kishk, A., Wachich, M., Abankwa, D., Schaffner-Reckinger, E., & Sauter, T. (2022). Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay. Pharmaceuticals (Basel, Switzerland), 15 (2). doi:10.3390/ph15020179
Peer reviewed

CHIPPALKATTI, R., Yacoub Kouzi Farah, BEN FREDJ EP SOUA, N., ABANKWA, D., & PARISI, B. (2022). PDE6D Dependent Trafficking of K-Ras to Stemness Promoting Centriolar Organelles [Paper presentation]. The Fourth RAS Initiative Symposium, Frederick, United States - Maryland.

Rouzbahani, Y., CHIPPALKATTI, R., ABANKWA, D., Carravilla, P., & Eggeling, C. (2022). Advanced microscope studies of the cell polarization instructing activity of Ras proteins. Biophysical Journal, 121 (3), 278. doi:10.1016/j.bpj.2021.11.1350

Glaab, E., Manoharan, G. B., & Abankwa, D. (23 August 2021). A Pharmacophore Model for SARS-CoV-2 3CLpro Small Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors. Journal of Chemical Information and Modeling, 61 (8), 4082-4096. doi:10.1021/acs.jcim.1c00258
Peer Reviewed verified by ORBi

Siddiqui, F. A., Vukic, V., Salminen, T. A., & Abankwa, D. (2021). Elaiophylin Is a Potent Hsp90/ Cdc37 Protein Interface Inhibitor with K-Ras Nanocluster Selectivity. Biomolecules. doi:10.3390/biom11060836
Peer Reviewed verified by ORBi

Ahearn, I. M., Court, H. R., Siddiqui, F., Abankwa, D., & Philips, M. R. (2021). NRAS is unique among RAS proteins in requiring ICMT for trafficking to the plasma membrane. Life Science Alliance. doi:10.26508/lsa.202000972
Peer Reviewed verified by ORBi

Chippalkatti, R., & Abankwa, D. (2021). Promotion of cancer cell stemness by Ras. Biochemical Society Transactions. doi:10.1042/BST20200964
Peer Reviewed verified by ORBi

Okutachi, S. O., Manoharan, G. B., Kiriazis, A., Laurini, C., Catillon, M., McCormick, F., Yli-Kauhaluoma, J., & Abankwa, D. (2021). A covalent calmodulin inhibitor as a tool to study cellular mechanisms of K-Ras-driven stemness. Frontiers in Cell and Developmental Biology. doi:10.3389/fcell.2021.665673
Peer Reviewed verified by ORBi

Parkkola, H., Siddiqui, F. A., Oetken-Lindholm, C., & Abankwa, D. (2021). FLIM-FRET Analysis of Ras Nanoclustering and Membrane-Anchorage. Methods in molecular biology (Clifton, N.J.), 2262, 233-250. doi:10.1007/978-1-0716-1190-6_13
Peer reviewed

Rosenqvist, P., Sabt, A., Dyunyasheva, V., ABANKWA, D., Virta, P., & Ora, M. (2021). Stability of the Phosphotriester PDE6D Inhibitors. ChemistrySelect, 6 (3), 488 - 493. doi:10.1002/slct.202004426
Peer Reviewed verified by ORBi

Abankwa, D., & Gorfe, A. A. (November 2020). Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again. Biomolecules, 10 (11). doi:10.3390/biom10111522
Peer Reviewed verified by ORBi

Siddiqui, F. A., Alam, C., Rosenqvist, P., Ora, M., Sabt, A., Manoharan, G. B., Bindu, L., Okutachi, S. O., Catillon, M., Taylor, T., Abdelhafez, O. M., Lönnberg, H., Stephen, A. G., Papageorgiou, A. C., Virta, P., & Abankwa, D. (2020). PDE6D Inhibitors with a New Design Principle Selectively Block K‑Ras Activity. ACS Omega, 5 (1), 832-842. doi:10.1021/acsomega.9b03639
Peer Reviewed verified by ORBi

Yurugi, H., Zhuang, Y., Siddiqui, F. A., Liang, H., Rosigkeit, S., Zeng, Y., Abou-Hamdan, H., Bockamp, E., Zhou, Y., Abankwa, D., Zhao, W., Désaubry, L., & Rajalingam, K. (2020). A subset of flavaglines inhibits KRAS nanoclustering and activation. Journal of Cell Science, 133 (12). doi:10.1242/jcs.244111
Peer Reviewed verified by ORBi

Schommer, C., Sauter, T., Pang, J., & Abankwa, D. (2020). Proceedings of the AI4Health Lecture Series (2020) [Paper presentation]. AI4Health Lectures Series (2020), Campus Belval, University of Luxembourg, Luxembourg.

Lilja, J., Jcaquement, G., Posada, I. M. D., Laasola, P., Vesilahti, E.-M., Miihkinen, M., Salomaa, S., Kreienkamp, H.-J., Barsukov, I., & ABANKWA, D. (2020). SHANK3 in oncogenic RAS signaling. Molecular Cancer Research.
Peer Reviewed verified by ORBi

Siddiqui, F. A., Parkkola, H., Manoharan, G. B., & Abankwa, D. (2019). Medium-Throughput Detection of Hsp90/Cdc37 Protein–Protein Interaction Inhibitors Using a Split Renilla Luciferase-Based Assay. SLAS Discovery. doi:10.1177/2472555219884033
Peer reviewed

Manoharan, G. B., Kopra, K., Eskonen, V., Harma, H., & Abankwa, D. (February 2019). High-throughput amenable fluorescence-assays to screen for calmodulin-inhibitors. Analytical Biochemistry, 572, 25-32. doi:10.1016/j.ab.2019.02.015
Peer Reviewed verified by ORBi

Buehler, U., Schulenburg, K., Yurugi, H., Solman, M., Abankwa, D., Ulges, A., Tenzer, S., Bopp, T., Thiede, B., Zipp, F., & Rajalingam, K. (2018). Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity. The EMBO journal, 37 (16). doi:10.15252/embj.201899429
Peer reviewed

Lilja, J., Jacquemet, G., Posada, I. M. D., Laasola, P., Vesilahti, E., Miihkinen, M., Salomaa, S., Kreienkamp, H., Barsukov, I., & ABANKWA, D. (2018). SHANK3 in oncogenic RAS signaling [Paper presentation]. Cancer conference.

Posada, I. M., Lectez, B., Siddiqui, F., Oetken-Lindholm, C., Sharma, M., Yetukuri, L., Zhou, Y., Aittokallio, T., & ABANKWA, D. (2018). PO-092 Inhibition of the mTORC1-pathway can feedback-activate H-RAS or K-RAS. ESMO Open, 3, 57. doi:10.1136/esmoopen-2018-EACR25.134

Sahlgren, C., Meinander, A., Zhang, H., Cheng, F., Preis, M., Xu, C., Salminen, T., Toivola, D., Abankwa, D., Rosling, A., Karaman, D., Salo-Ahen, O., Österbacka, R., Eriksson, J., Willför, S., Petre, I., Peltonen, J., Leino, R., Johnson, M., ... Sandler, N. (2017). Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems. Advanced Healthcare Materials. doi:10.1002/adhm.201700258
Peer Reviewed verified by ORBi

Posada, I., Lectez, B., Siddiqui, F., Oetken-Lindholm, C., Sharma, M., & Abankwa, D. (2017). Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1. Scientific Reports. doi:10.1038/s41598-017-09387-8
Peer Reviewed verified by ORBi

Posada, I., Lectez, B., Sharma, M., Oetken-Lindholm, C., Yetukuri, L., Zhou, Y., Aittokallio, T., & Abankwa, D. (04 July 2017). rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner. Oncotarget, Vol. 8 ((No. 27)), 44550-44566. doi:10.18632/oncotarget.17819
Peer Reviewed verified by ORBi

Contact ORBilu